IL10 and hepatocellular carcinoma: Notably, we found that the glycolytic inhibitor 2DG upregulated the expression of IL-12 while downregulating the expression of IL-10 in HCC-TAMs (Fig. 4e), and blocked the ability of HCC-TAMs to induce HCC EMT (Fig. 4f; Supplementary Fig. 4A) accompanied with upregulated E-cadherin/N-cadherin ratio in HCC cells (Supplementary Fig. 4B).